US Patent 8,642,025: Scope, Claim Construction, Expiration, and HCV NS5A Patent Landscape
US Patent 8,642,025 is a Bristol-Myers Squibb patent directed to a broad genus of hepatitis C virus NS5A inhibitors, pharmaceutical compositions, combination regimens, and methods of treating HCV infection. The patent was granted on February 4, 2014. Its claims are materially broader than a single marketed molecule because claim 1 uses an extensive Markush structure covering multiple heterocyclic, carbocyclic, substituted aryl, heteroaryl, amine, ester, amide, and sulfonyl variants.
The patent’s commercial relevance is tied to the early HCV NS5A inhibitor program that produced daclatasvir, marketed in the United States as Daklinza. The claims supplied do not establish that every daclatasvir formulation or approved product is covered, but they are structurally consistent with the broad early BMS NS5A inhibitor patent estate.
What technology does US Patent 8,642,025 protect?
The patent protects compounds designed to inhibit the HCV NS5A protein. NS5A is a nonstructural HCV protein involved in viral RNA replication and virion assembly. NS5A inhibitors generally act through a mechanism distinct from nucleoside polymerase inhibitors such as sofosbuvir and protease inhibitors such as simeprevir or grazoprevir.
The patent covers four principal subject-matter categories:
| Claim category |
Claims |
Protected subject matter |
| Chemical compounds |
1-28 |
Markush genus and progressively narrower compound subgenera |
| Pharmaceutical compositions |
29-34 |
Compounds with carriers and anti-HCV combination agents |
| NS5A inhibition |
35 |
Contacting HCV NS5A with a claimed compound |
| HCV treatment |
36-40 |
Administering a claimed compound, alone or with anti-HCV agents |
Claim 1 is the central chemical claim. Claims 2-28 narrow the central scaffold, linker atoms, substituent positions, and terminal acyl groups.
How broad is claim 1 of US Patent 8,642,025?
Claim 1 is an extensive Markush claim covering a large chemical genus. It does not identify one fixed compound. It defines a Formula (I) scaffold through variable positions and substituent lists.
The principal structural variables are:
- m and n: independently 0, 1, or 2;
- q and s: independently 0 through 4;
- u and v: independently 0 through 3;
- X and Y: oxygen, sulfur, sulfoxide, sulfone, methylene, substituted methylene, or geminally substituted carbon, subject to restrictions when m or n is zero;
- R1 and R2: alkoxy, alkoxycarbonyl, alkyl, carboxy, halo, haloalkyl, hydroxy, amino, aminoalkyl, and aminocarbonyl groups;
- R3 and R4: hydrogen or acyl groups;
- R5 and R6: alkoxy, alkyl, halo, haloalkyl, hydroxy, or amino substituents;
- R7 and R8: hydrogen and selected carbonyl, alkyl, carboxy, haloalkyl, and silyl-containing groups;
- R9: a large set of alkyl, aryl, heterocyclic, cycloalkyl, aminoalkyl, and substituted aromatic groups.
The claim also permits monocyclic and fused bicyclic heterocycles and extensive secondary substitution. Those nested definitions materially increase the number of theoretical species in the genus.
What is the core scaffold?
Claims 2-8 focus on compounds where m and n are each 1. Claims 3 and 4 then narrow X and Y to sulfur-containing linkers, with claim 4 requiring both X and Y to be sulfur.
Claim 5 further restricts q, s, u, and v to zero. Claims 6-8 address the terminal substituents:
- Claim 6 requires at least one R3 or R4 to be hydrogen.
- Claim 7 requires both R3 and R4 to be acyl groups.
- Claim 8 limits R9 to arylalkyl or heterocyclyl groups.
This sequence suggests that the patent’s commercially important embodiments may lie in a relatively compact sulfur-containing subgenus within the much broader claim 1 genus.
What alternative scaffold does claims 9-15 cover?
Claims 9-15 cover compounds in which X is a substituted methylene group and Y is a methylene or substituted methylene group. Claims 10 and 11 narrow the substituents to halo or hydroxy groups and limit R1 and R2 to C1 alkyl or halo-related alternatives.
Claims 13-15 then address hydrogen or acyl substitution at R3 and R4. This branch is chemically distinct from the sulfur-containing series and provides a separate fallback position if the broad claim 1 genus is challenged.
What does claims 16-28 cover?
Claims 16-28 require X and Y to be methylene groups. Claims 17-19 progressively reduce the q, s, u, and v variables and limit R1 and R2 to alkyl, halo, or haloalkyl groups.
Claims 20-28 then define hydrogen and acylated variants. Claim 22 maintains a broad list of R9 groups, while claims 23-27 specify arylalkyl, heterocyclyl, heterocyclylalkyl, and aminoalkyl combinations. Claim 28 creates a mixed terminal-substituent category in which the two R9 groups come from different defined classes.
What are the strongest and weakest parts of the patent claims?
The strongest claim positions are the narrower compound claims that combine a defined core with limited substituent classes. Claims 4-8, 12-15, and 18-28 provide multiple fallback positions and are more likely to withstand an invalidity challenge than claim 1 standing alone.
| Claim group |
Scope |
Relative patent strength |
| Claim 1 |
Very broad chemical genus |
Vulnerable to written-description, enablement, and prior-art attacks |
| Claims 2-4 |
Sulfur-containing core |
Stronger, but still broad |
| Claims 5-8 |
Reduced substitution and defined terminal groups |
Stronger structural fallback |
| Claims 9-15 |
Halo/hydroxy substituted methylene series |
Moderate to strong, depending prior art |
| Claims 16-21 |
Methylene-linked series |
Moderate |
| Claims 22-28 |
Broad acyl and terminal-substituent combinations |
Variable; breadth increases validity risk |
| Claims 29-34 |
Compositions and combinations |
Strong only when tied to an infringing compound |
| Claims 35-40 |
NS5A inhibition and treatment |
Useful against commercial use, but dependent on claim 1 compound coverage |
The main legal risk for claim 1 is genus breadth. A challenger could argue that the specification does not adequately describe or enable the full range of compounds covered by the nested Markush definitions. The patent holder would counter that the disclosed examples, common structural core, synthetic methods, and demonstrated NS5A activity support the genus.
Claim 35 is also broad because it requires contacting NS5A with a compound of claim 1 but does not recite a particular potency threshold, viral genotype, assay, or concentration. Claim 36 requires treatment of HCV infection and therefore has a more direct therapeutic application.
What do the composition and combination claims cover?
Claim 29 covers a pharmaceutical composition comprising a claim 1 compound and a pharmaceutically acceptable carrier.
Claims 30-34 add anti-HCV combination therapy. The listed combinations include:
- interferon;
- ribavirin;
- a second anti-HCV compound;
- interleukins;
- agents promoting a type 1 helper T-cell response;
- interfering RNA and antisense RNA;
- imiquimod;
- inosine 5'-monophosphate dehydrogenase inhibitors;
- amantadine and rimantadine.
These claims reflect the treatment environment at the time of filing, when interferon and ribavirin were central components of HCV therapy. They are less aligned with current all-oral direct-acting antiviral regimens, although claim 31 could potentially reach combinations with another anti-HCV compound if the other limitations are met.
The composition claims do not independently protect every combination containing an NS5A inhibitor. The combination must include a compound falling within claim 1, together with the specified carrier or anti-HCV agent.
What methods of use does US Patent 8,642,025 protect?
Claims 35-40 cover two categories of use.
NS5A inhibition
Claim 35 covers contacting HCV NS5A protein with a claim 1 compound. This is principally a biochemical or research-use claim. Its commercial value depends on how broadly “contacting” is construed and whether the accused activity is performed using a compound within the claimed genus.
HCV treatment
Claim 36 covers administering a therapeutically effective amount of a claim 1 compound to relieve or cause regression of an HCV infection.
Claim 37 permits administration of a second anti-HCV agent before, after, or simultaneously with the claimed compound. Claims 38-40 specify interferon and other anti-HCV agents.
The method claims could be relevant to product labels, clinical protocols, and treatment use. They are less likely to reach a generic manufacturer solely on the basis of manufacturing or selling an unapproved compound unless the relevant inducement or contributory-infringement facts are present.
When does US Patent 8,642,025 lose exclusivity?
The patent was granted February 4, 2014. For a post-1995 U.S. utility patent, the ordinary term is 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, terminal disclaimers, patent-term extension, and other statutory adjustments.[1]
The relevant HCV NS5A family is associated with a 2006 priority period. On that basis, the ordinary patent-term endpoint is expected to fall in 2027, subject to the patent’s specific continuity and term-adjustment records.
| Milestone |
Date or status |
| Earliest family priority period |
2006 family period |
| U.S. grant |
February 4, 2014 |
| Ordinary statutory term framework |
20 years from earliest effective nonprovisional filing |
| Expected ordinary expiration window |
2027 |
| Patent-term adjustment |
Must be checked in the USPTO record |
| Patent-term extension |
No extension is established from the claims supplied |
| Regulatory exclusivity |
Separate from patent term |
Patent expiration does not automatically create generic market entry. A generic applicant must also address listed patents, regulatory exclusivity, product-specific claims, and any other continuing family members.
What is the Orange Book status of US Patent 8,642,025?
Orange Book listing is product-specific. A patent may cover an active ingredient or method of use without appearing in the Orange Book for a particular NDA.
Daklinza, containing daclatasvir dihydrochloride, was approved by the FDA in 2015 for use with other agents in chronic HCV infection.[2] The relevant Orange Book question is whether US Patent 8,642,025 was submitted for listing against the Daklinza NDA and whether it remained listed during the applicable reference-product period.
The supplied claim text alone does not establish Orange Book listing. The FDA Orange Book must be checked by NDA number and patent number, together with any delisting, expiration, or patent-use-code information.[3]
The practical distinction is important:
- a listed patent can trigger a Paragraph IV certification and a potential 30-month stay;
- an unlisted composition or method patent generally does not create the same Hatch-Waxman approval-blocking mechanism;
- an unlisted patent can still support a separate infringement action;
- an expired patent cannot support a new statutory stay.
Which companies challenged daclatasvir or this patent?
The available claim information does not establish a specific Paragraph IV challenger, infringement complaint, or settlement agreement directed to US Patent 8,642,025.
No company should be treated as a confirmed challenger based solely on the existence of this patent. A reliable challenge analysis requires matching:
- the patent number to the Orange Book listing;
- the NDA and patent-use code;
- the ANDA applicant;
- the Paragraph IV notice date;
- the district-court complaint;
- any settlement or license terms.
Potential generic entry would more likely involve the full daclatasvir patent family rather than this patent in isolation. A compound claim, formulation claim, polymorph claim, salt claim, and method-of-use claim can create separate litigation positions.
How does this patent compare with the broader HCV NS5A patent landscape?
The HCV NS5A landscape includes several distinct patent groups:
| Patent group |
Typical protected subject matter |
Principal commercial relevance |
| Early NS5A chemical-genus patents |
Broad Markush compounds |
Foundational compound protection |
| Specific active-compound patents |
Daclatasvir or other named molecules |
Direct product protection |
| Salt and polymorph patents |
Crystalline forms and pharmaceutical salts |
Solid-state and formulation control |
| Formulation patents |
Oral dosage forms, excipients, release profiles |
Product and manufacturing protection |
| Combination patents |
NS5A inhibitor plus another DAA |
Regimen protection |
| Method-of-use patents |
Genotype, treatment duration, patient population |
Label and clinical-use protection |
| Manufacturing patents |
Intermediates, stereochemical control, crystallization |
Supply-chain barriers |
US Patent 8,642,025 is primarily an early compound and use patent. It is not, based on the supplied claims, a conventional formulation patent, crystalline-form patent, or process patent.
Its principal value is therefore strongest before or near product launch, when broad chemical-genus claims can deter development of related compounds. Its value declines after expiration or after competing products move to distinct chemotypes outside the claimed genus.
What generic entry risks exist?
A generic or follow-on developer would face several possible infringement theories if its product contains a compound within the claim 1 genus:
- literal infringement of claim 1;
- infringement of a narrower compound claim;
- infringement of composition claim 29;
- infringement of method claims through labeling or induced use;
- infringement of combination claims if the product label directs combination therapy.
Design-around opportunities may include:
- using a chemically distinct NS5A inhibitor;
- selecting substituents outside the defined R-group classes;
- avoiding the claimed X/Y linker configurations;
- using a different antiviral mechanism;
- limiting the label to uses not covered by enforceable method claims, where legally and regulatorily feasible.
The broad claim 1 genus creates substantial clearance risk for close analogues. Claims 4-8 and 16-28 create additional risk for compounds that avoid claim 1 only through a narrow structural distinction.
What licensing and commercial issues affect the patent estate?
The relevant commercial rights were associated with Bristol-Myers Squibb’s HCV antiviral program. Daclatasvir was commercialized by BMS as Daklinza, and the U.S. product was approved with combination-use restrictions rather than as a standalone HCV therapy.[2]
No license, covenant not to sue, or settlement agreement can be inferred from the claim text. A complete freedom-to-operate review must distinguish:
- ownership of US Patent 8,642,025;
- ownership of continuation and divisional patents;
- licenses covering daclatasvir or related compounds;
- regional rights outside the United States;
- any settlement involving an ANDA applicant.
The patent’s geographic effect is limited to the United States. Foreign counterparts must be assessed separately because prosecution outcomes, claim scope, term, opposition proceedings, and supplementary protection certificates differ by jurisdiction.
What is the likely revenue exposure?
Daclatasvir was commercially important during the transition from interferon-based treatment to all-oral direct-acting antiviral therapy. Its revenue exposure was highest before broad uptake of competing regimens based on sofosbuvir, ledipasvir, velpatasvir, glecaprevir, pibrentasvir, and other combinations.
US Patent 8,642,025 would have had its greatest commercial significance during:
- pre-launch development of daclatasvir;
- the initial U.S. exclusivity period;
- the period when close NS5A analogues could have competed with daclatasvir;
- any generic-entry window before the expected 2027 patent-term endpoint.
Current revenue exposure is lower because Daklinza is no longer a major U.S. commercial product and HCV treatment has shifted toward pangenotypic regimens. The patent remains relevant to historical diligence, family-level litigation analysis, and any later-market commercialization of a covered compound.
Key Takeaways
- US Patent 8,642,025 is a broad HCV NS5A inhibitor patent associated with Bristol-Myers Squibb.
- Claim 1 covers a large Markush genus rather than one defined commercial molecule.
- Claims 2-28 provide narrower sulfur-containing, methylene-linked, substituted, and acylated compound subgenera.
- Claims 29-34 cover pharmaceutical compositions and combinations with interferon, ribavirin, and other anti-HCV agents.
- Claims 35-40 cover NS5A inhibition and treatment of HCV infection.
- The patent’s ordinary term is expected to reach the 2027 period based on the 2006 family priority period, subject to USPTO term calculations.
- The claims supplied do not establish Orange Book listing, a Paragraph IV challenge, litigation, or a settlement.
- The strongest practical protection is likely provided by the narrower compound claims and any related specific-product, salt, formulation, or continuation patents.
- Generic entry would require a family-level analysis, not review of US Patent 8,642,025 alone.
FAQs
Does US Patent 8,642,025 specifically claim daclatasvir?
The supplied claims define a broad chemical genus. Whether daclatasvir falls within a particular claim requires mapping its complete structure, stereochemistry, salt form, and substituents against Formula (I) and the dependent claims.
Is US Patent 8,642,025 a formulation patent?
No. Its primary claims are directed to chemical compounds. Claim 29 covers compositions containing a claimed compound, but the patent does not principally claim a specific dosage form, excipient system, polymorph, or release profile.
Can a generic applicant avoid this patent by using a different NS5A inhibitor?
Potentially. A chemically distinct NS5A inhibitor may fall outside the Formula (I) genus. That conclusion requires a claim chart against the candidate molecule and all relevant continuation, formulation, salt, and method patents.
Does patent expiration eliminate FDA regulatory exclusivity?
No. Patent expiration and FDA exclusivity are separate. FDA approval exclusivity, orphan-drug exclusivity, pediatric exclusivity, and listed-patent obligations are governed by different provisions and may end on different dates.[1,3]
Does this patent cover treatment with sofosbuvir?
The claims do not expressly identify sofosbuvir. Claim 31 and claim 37 broadly refer to a second anti-HCV compound, but infringement would require the primary administered compound to fall within claim 1 and the combination to satisfy the remaining claim limitations.
References
- United States Code. (2024). 35 U.S.C. §§ 154, 156, and 271.
- U.S. Food and Drug Administration. (2015). Daklinza (daclatasvir) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,642,025: Hepatitis C virus inhibitors. Bristol-Myers Squibb Company.